Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Velcade in Combination With Chlorambucil in Relapsed/Refractory Waldenstrom's Macroglobulinemia or Small Lymphocytic Lymphoma
2006-003495-35Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- Jul 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and chlorambucil in Waldenström macroglobulinemia (WM) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by European Institute of Oncology. Primary endpoints: Overall response rate (ORR) and Safety and toxicity. Started Jul 2007; status: terminated.
02
Drugs
bortezomibchlorambucil
03
Conditions
Waldenström macroglobulinemia (WM)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2006-003495-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003495-35.